TAKEDA PHARMACEUTICALS INTERNATIONAL AG

Their core work

Takeda is a global pharmaceutical company that contributes deep drug development and clinical expertise to large-scale European health research consortia. Within H2020, they focus on rare diseases, neurodegenerative conditions, inflammatory disorders, and advanced therapies including gene and cell therapy. They bring industry-grade clinical trial infrastructure, real-world patient data capabilities, and regulatory knowledge to public-private partnerships — particularly IMI (Innovative Medicines Initiative) projects. Their role is consistently that of a pharma industry partner providing clinical assets, patient cohorts, and translational expertise to multi-stakeholder research platforms.

What they specialise in

How they've shifted over time

In their early H2020 period (2016–2019), Takeda focused on hematological cancers (HARMONY), biobanking, liver disease biomarkers (LITMUS), and foundational patient data platforms. From 2020 onward, their portfolio shifted decisively toward digital health endpoints, rare disease diagnostics, advanced therapies (gene/cell therapy, CAR-T), and COVID-19 response. The recent period shows a clear pivot from traditional clinical data collection toward digital measurement tools, AI-assisted diagnostics, and next-generation therapeutics like immunotherapy and gene therapy.

Takeda is moving toward digitally measured clinical outcomes and personalized advanced therapies (gene therapy, CAR-T), making them an ideal partner for projects bridging digital health technology with rare disease treatment development.

How they like to work

Takeda participates exclusively as a consortium partner — never as coordinator across all 24 projects — which is typical for large pharma in IMI and similar public-private partnerships where academic or public institutions lead. They operate in very large consortia (503 unique partners across 33 countries), functioning as an industry anchor that provides clinical infrastructure, patient access, and regulatory pathway knowledge. Their broad partner network and zero coordination roles suggest they are a reliable, well-connected industry contributor rather than a project initiator.

Takeda has collaborated with 503 unique partners across 33 countries, making them one of the most broadly connected pharma participants in H2020 health research. Their network spans nearly all EU member states plus associated countries, reflecting their role as a major industry partner in pan-European health consortia.

What sets them apart

Takeda brings the rare combination of being a top-10 global pharmaceutical company that actively participates in pre-competitive European research — not just funding it. Their Swiss-based international operations unit gives them direct access to both EU regulatory pathways and global clinical trial networks. For consortium builders, Takeda offers industry credibility, patient cohort access, and the translational muscle to move research findings toward actual drug development and regulatory approval.

Highlights from their portfolio

• SCREEN4CARE
  Combines newborn genetic screening with AI-powered phenotype checking to dramatically shorten rare disease diagnosis — a direct bridge between genomics and clinical practice.
• MOBILISE-D
  Pioneering regulatory-grade digital mobility assessment across multiple diseases (COPD, Parkinson's, MS), potentially changing how clinical trials measure patient outcomes.
• T2EVOLVE
  Directly accelerates CAR-T and TCR-engineered cell therapy access — one of the most commercially significant advanced therapy areas in oncology today.